175 related articles for article (PubMed ID: 36225103)
21. Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population.
Lytle D; Grajales Beltrán AG; Perdrizet J; Ait Yahia N; Cane A; Yarnoff B; Chapman R
Hum Vaccin Immunother; 2023 Aug; 19(2):2257426. PubMed ID: 37771288
[TBL] [Abstract][Full Text] [Related]
22. Pneumococcal Vaccination in Adults: What Can We Learn From Observational Studies That Evaluated PCV13 and PPV23 Effectiveness in the Same Population?
Dunne EM; Cilloniz C; von Mollendorf C; Lewnard J; Grant LR; Slack MPE; Jodar L; Theilacker C; Gessner BD
Arch Bronconeumol; 2023 Mar; 59(3):157-164. PubMed ID: 36681604
[TBL] [Abstract][Full Text] [Related]
23. Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine Among US Children with Underlying Medical Conditions.
Rozenbaum MH; Chilson E; Farkouh R; Huang L; Cane A; Arguedas A; Tort MJ; Snow V; Averin A; Weycker D; Hariharan D; Atwood M
Infect Dis Ther; 2024 Apr; 13(4):745-760. PubMed ID: 38491269
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus "no vaccination" and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine.
Gouveia M; Jesus G; Inês M; Costa J; Borges M
Hum Vaccin Immunother; 2019; 15(4):850-858. PubMed ID: 30633615
[TBL] [Abstract][Full Text] [Related]
25. Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis.
Rozenbaum MH; van Hoek AJ; Fleming D; Trotter CL; Miller E; Edmunds WJ
BMJ; 2012 Oct; 345():e6879. PubMed ID: 23103369
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness and impact on infections and associated antimicrobial resistance of 20-valent pneumococcal conjugate vaccine in US children previously immunized with PCV13.
Rozenbaum MH; Huang L; Cane A; Arguedas A; Chapman R; Dillon-Murphy D; Tort MJ; Snow V; Chilson E; Farkouh R
J Med Econ; 2024; 27(1):644-652. PubMed ID: 38577742
[TBL] [Abstract][Full Text] [Related]
27. Pneumococcal Vaccination Strategies in 50-Year-Olds to Decrease Racial Disparities: A US Societal Perspective Cost-Effectiveness Analysis.
Altawalbeh SM; Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
Value Health; 2024 Jun; 27(6):721-729. PubMed ID: 38462225
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.
Cho BH; Stoecker C; Link-Gelles R; Moore MR
Vaccine; 2013 Dec; 31(50):6011-21. PubMed ID: 24148572
[TBL] [Abstract][Full Text] [Related]
29. Cost-Effectiveness of Vaccinating Immunocompetent ≥65 Year Olds with the 13-Valent Pneumococcal Conjugate Vaccine in England.
van Hoek AJ; Miller E
PLoS One; 2016; 11(2):e0149540. PubMed ID: 26914907
[TBL] [Abstract][Full Text] [Related]
30. Cost-Effectiveness of Newly Recommended Pneumococcal Vaccination Strategies in Older Underserved Minority Adults in the USA.
Smith KJ; Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK
Infect Dis Ther; 2022 Aug; 11(4):1683-1693. PubMed ID: 35831685
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of pneumococcal vaccination for elderly in Sweden.
Wolff E; Storsaeter J; Örtqvist Å; Naucler P; Larsson S; Lepp T; Roth A
Vaccine; 2020 Jul; 38(32):4988-4995. PubMed ID: 32536548
[TBL] [Abstract][Full Text] [Related]
32. Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: A case-control study.
Kim JH; Chun BC; Song JY; Kim HY; Bae IG; Kim DM; Choi YH; Jun YH; Choi WS; Kang SH; Kwon HH; Jeong HW; Kee SY; Hur J; Chung JW; Yoon YK; Sohn JW; Yang KS; Kim MJ
Vaccine; 2019 May; 37(21):2797-2804. PubMed ID: 31005428
[TBL] [Abstract][Full Text] [Related]
33. 20-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults.
Shirley M
Drugs; 2022 Jun; 82(9):989-999. PubMed ID: 35793027
[TBL] [Abstract][Full Text] [Related]
34. Systematic review of economic evaluations of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in individuals 60 years of age or older.
Nishikawa AM; Sartori AMC; Mainardi GM; Freitas AC; Itria A; Novaes HMD; de Soárez PC
Vaccine; 2018 May; 36(19):2510-2522. PubMed ID: 29618414
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model.
Delgleize E; Leeuwenkamp O; Theodorou E; Van de Velde N
BMJ Open; 2016 Nov; 6(11):e010776. PubMed ID: 27903558
[TBL] [Abstract][Full Text] [Related]
36. A cost-effectiveness analysis of revaccination and catch-up strategies with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in older adults in Japan.
Jiang Y; Yang X; Taniguchi K; Petigara T; Abe M
J Med Econ; 2018 Jul; 21(7):687-697. PubMed ID: 29723081
[TBL] [Abstract][Full Text] [Related]
37. Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain.
Rodríguez González-Moro JM; Menéndez R; Campins M; Lwoff N; Oyagüez I; Echave M; Rejas J; Antoñanzas F
Clin Drug Investig; 2016 Jan; 36(1):41-53. PubMed ID: 26547199
[TBL] [Abstract][Full Text] [Related]
38. Invasive pneumococcal disease, comorbidities, and polysaccharide vaccine use in children aged 5-15 years in England and Wales.
Ladhani SN; Andrews NJ; Waight P; Borrow R; Slack MP; Miller E
Clin Infect Dis; 2014 Feb; 58(4):517-25. PubMed ID: 24300040
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK.
Jiang Y; Gauthier A; Keeping S; Carroll S
Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):913-27. PubMed ID: 25189087
[TBL] [Abstract][Full Text] [Related]
40. A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination.
Cannon K; Elder C; Young M; Scott DA; Scully IL; Baugher G; Peng Y; Jansen KU; Gruber WC; Watson W
Vaccine; 2021 Dec; 39(51):7494-7502. PubMed ID: 34839993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
